Beigene Stock News

BeiGene develops drugs designed to fight cancer using molecular targeting and immuno-oncology technologies.

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. ET. A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.be

BeiGene (NASDAQ: BGNE ) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings BeiGene missed estimated earnings by 19.15%, reporting an EPS … Full story available on Benzinga.com

BeiGene press release (BGNE): Q4 GAAP EPADS of -$6.16 misses by $1.29.Revenue of $214M (+113.8% Y/Y) beats by $0.64M.Cash, Cash Equivalents, Restricted Cash and Short-Term…

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the fourth quarter and full year of 2021, recent business highlights, and anticipated upcoming milestones. “Last year was transformative for our company, and we have built strategic competitive advantages that will help BeiGene to achieve our mission of ma

The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd''s (NASDAQ: BGNE ) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its

The U.S. Food and Drug Administration ((FDA)) accepted BeiGene''s (BGNE) application seeking approval of Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic

BeiGene''s (BGNE) Brukinsa (zanubrutinib) was approved by Swissmedic to treat adult patients with Waldenström’s macroglobulinemia ((WM)) who have received at least one prior line of…

BeiGene (BGNE) announces its supplemental new drug application (sNDA) for BTK inhibitor BRUKINSA (zanubrutinib) has accepted by China National Medical Products Administration

BeiGene (BGNE) announces positive findings from the Phase 3 RATIONALE 305 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for patients

BeiGene (BGNE) announced that the Center for Drug Evaluation of the China National Medical Products Administration ((NMPA)) has accepted a supplemental new drug application ((sNDA))

Leap Therapeutics Inc (NASDAQ: LPTX ) will present updated data from the DisTinGuish Phase 2a study of DKN-01 , in combination with tislelizumab in gastric or gastric gastroesophageal junction cancer (G/GEJ). Data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Tislelizumab is BeiGene Ltd''s (NASDAQ: BGNE ) anti-PD-1 antibody. In first-line patients treated with DKN-01 combo therapy showed overall preliminary median progression-free survival (PFS) of 10.7 months. The Full story available on Benzinga.com

The stock price of BeiGene (NASDAQ: BGNE), a China-based biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a fall of 15% over the last twen